Drug intelligence / Profile preview

prednisone + sulfasalazine

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of prednisone (a corticosteroid) and sulfasalazine (an anti-inflammatory drug). This combination is used primarily for treating Crohn's disease, ulcerative colitis, and rheumatoid arthritis. In Crohn's disease, adding prednisone to sulfasalazine results in significantly faster initial improvement compared to sulfasalazine alone. For rheumatoid arthritis, this combination is used as part of various therapeutic approaches, including double and triple therapy regimens.

Targets

System xc- cystine-glutamate transporterCHUK (IKKα)GR (Glucocorticoid receptor)MR (Mineralocorticoid receptor)IKBKB (IKKβ)

Beyond the preview

Go deeper on prednisone + sulfasalazine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on prednisone + sulfasalazine.

Explore the full profile